The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
NAEH can cause heavy or abnormal bleeding and, if left untreated, may progress to uterine cancer
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Under the proposed terms, Vaximm would secure a $20 million upfront payment, up to $815 million tied to clinical, regulatory, and commercial milestones
Pharmaplan brings a pan-European footprint of locations and specialist teams, now operating within Exyte’s Biopharma & Life Sciences division
Subscribe To Our Newsletter & Stay Updated
